Salts of the anti-HIV drug lamivudine with phthalic and salicylic acids by da Silva, Cameron Capeletti et al.
  Universidade de São Paulo
 
2012
 
Salts of the anti-HIV drug lamivudine with
phthalic and salicylic acids
 
 
CRYSTENGCOMM, CAMBRIDGE, v. 14, n. 14, supl. 1, Part 3, pp. 4562-4566, NOV, 2012
http://www.producao.usp.br/handle/BDPI/42011
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Física e Ciência Interdisciplinar - IFSC/FCI Artigos e Materiais de Revistas Científicas - IFSC/FCI
Salts of the anti-HIV drug lamivudine with phthalic and salicylic acids{
Cameron Capeletti da Silva,a Renan Rezende Coelho,a Marilia de Lima Cirqueira,a Ariane Carla Campos de
Melo,a Iara Maria Landre Rosa,b Javier Ellenac and Felipe Terra Martins*a
Received 19th March 2012, Accepted 18th April 2012
DOI: 10.1039/c2ce25386k
Salts of the anti-HIV drug lamivudine, with phthalic acid and
salicylic acid as counterions, were investigated in this study.
Neither the packing of the (lamivudine)+(phthalic acid)2 ion
pairs nor the conformation of the lamivudine moiety itself were
similar to those found in other multicomponent molecular salts
of the drug, such as hydrogen maleate and saccharinate ones,
even though all three salts crystallize in the same P212121
orthorhombic space group with similar unit cell metrics.
Lamivudine salicylate assumes a different crystal structure to
those of the hydrogen maleate and saccharinate salts, crystal-
lizing in the P21 monoclinic space group as a monohydrate
whose (lamivudine)+(salicylic acid)2 ion pair is assembled
through two hydrogen bonds with cytosine as a dual donor
to both oxygens of the carboxylate, such as in the pairing of
lamivudine with a phthalic acid counterion. In lamivudine
salicylate monohydrate, the drug conformation is related to the
hydrogen maleate and saccharinate salts. However, such a
conformational similarity is not related to the intermolecular
interaction patterns. Lamivudine and water molecules alternate
into helical chains in the salicylate salt monohydrate.
Lamivudine (b-L-29,39-dideoxy-39-thiacytidine, 3TC) is a nucleo-
side reverse transcriptase inhibitor (NRTI) widely used in anti-HIV
(human immunodeficiency virus) and anti-HBV (hepatitis B virus)
therapies.1 Lamivudine is a cytidine analog featuring an isosteric
replacement of the ribose 39-methylene group with a sulfur atom.
This drug has two chiral carbons, namely, C19 and C49, whose
absolute configurations are S and R, respectively. As a
consequence of its chirality, all known crystal structures of
lamivudine have been solved in non-centrosymmetric space
groups. This can be seen in the eleven crystal structures which
have already been reported for lamivudine thus far, wherein seven
of them were solved in the P21 monoclinic space group (form III,
(a hemihydrate),2 a 3,5-dinitrosalicylate salt hydrate with 2 : 1 : 1
lamivudine : 3,5-dinitrosalicylic acid : H2O lstoichiometry,
3 la
4-quinolinone cocrystal,3 a zidovudine cocrystal hydrate with
1 : 1 : 1 lamivudine : zidovudine : H2O stoichiometry,
3 a
lamivudine duplex with 8 : 2 : 2 : 1 : 4 lamivudine : maleic
acid : HCl : (CH3)2CHOH : H2O stoichiometry,
4 a hydrochloride
salt anhydrate5 and a hydrochloride salt monohydrate5), three in
the P212121orthorhombic space group (form I (a 0.2-hydrate),
6 a
saccharinate salt,7 and a hydrogen maleate salt8) and one in the
P43212 tetragonal space group (form II, an anhydrous poly-
morph).6 As can be observed, this drug has been extensively
investigated due to its ability to crystallize together with different
small molecules in multicomponent molecular solid state phases.
Recently, crystal engineering studies have focused on many
drugs.9 Concerning lamivudine, we designed a hydrogen
maleate salt8 by invoking physicochemical principles and
recognizing key assembling frameworks in the antecedent
structure of lamivudine saccharinate.7 The choice of maleic
acid to crystallize together with lamivudine was based on
chemical and structural similarities to saccharin, such as the
acid-ionization constant (pKa) and intramolecular features
including hydrogen bonding functionalities and stereochem-
istry. Lamivudine hydrogen maleate was successfully obtained
and a lamivudine saccharinate-like P212121 orthorhombic
structure was assumed by the designed salt. On the basis of
packing and conformational similarities between hydrogen
maleate and saccharinate versions of the drug, it was possible
to point out a molecular motif present in both the maleic acid
and saccharin counterions responsible for the crystal assem-
bly of these two isostructural lamivudine salts.8
As part of the ongoing studies in crystal engineering of
molecular crystals of lamivudine, other salt formers were
investigated in this study. Here, phthalic acid and salicylic acid
were selected as salt formers. Their salts with lamivudine were
prepared{ and structurally elucidated by single-crystal X-ray
diffraction.§ The experimental X-ray powder diffractograms of
the salts were overlaid onto the calculated results from their
corresponding crystals structures." The observed Bragg peak
positions are in good agreement with the simulated positions,
although there are differences in the reflection intensities which
resulted from the preferred orientation effects on the X-ray
powder diffraction measurements of both salts (Fig. 1). Since
neither a pronounced broad hump from an amorphous solid nor
extra Bragg peaks from other crystalline phases other than that of
the sample were observed in the experimental diffractograms, it
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was possible to conclude that the salts were in the bulk of the
crystal phases elucidated here.
The acid strengths of the counterions were taken into account
when choosing these salts. Both maleic acid and saccharin are
deprotonated in the lamivudine salts due to a transfer of one
proton from each acid to each lamivudine molecule.7,8 It is a fact
that their acid strengths for a one-proton dissociation are very
similar. Saccharin has a pKa value of 2.2,
7,10 while the first proton
acid-ionization constant (pKa1) of maleic acid is 1.83.
11 However,
the acid strengths of phthalic acid and salicylic acid are not similar
to those of maleic acid and saccharin. Differing by more than one
unit to maleic acid pKa1, phthalic acid has a pKa1 of 2.95.
12
Similarly, the pKa of salicylic acid is 2.97.
13 Although there are
differences in the proton dissociation tendencies of the counterions,
fortunately proton transfer to lamivudine occurred in the hydrogen
phthalate and salicylate salts as it had in the hydrogen maleate and
saccharinate molecules and crystals of lamivudine hydrogen
phthalate and lamivudine salicylate were obtained. This can be
viewed in Fig. 2 as an ellipsoid plot of their asymmetric units.
Lamivudine hydrogen phthalate was solved in the P212121
orthorhombic space group with four (lamivudine)+(phthalic acid)2
ion pairs per unit cell. To assemble each ion pair, the drug donates
two hydrogen bonds through the imine and amine moieties of its
protonated cytosine ring to the two COO2 oxygens of the
hydrogen phthalate counterion, in a pattern equivalent to that
observed in lamivudine hydrogen maleate.8 In addition to
crystallizing in the same crystal system and space group as the
hydrogen maleate and saccharinate salts, the hydrogen phthalate
salt features similar unit cell dimensions.I However the structural
similarities between lamivudine hydrogen phthalate and the two
previously reported isostructural salts end there. Neither the drug
conformation (Fig. 3) nor the arrangement of the ion pairs in
lamivudine hydrogen phthalate resembles those of the antecedent
salts (Fig. 4).
In the hydrogen phthalate salt, the drug skeleton exhibits a very
unusual nucleoside conformation, with a intermediate cytosine
orientation between the anti and syn conformations in which the
C2–N1–C19–O19 dihedral angle measures 82.8(2)u. Its oxathiolane
ring possesses a C29-exo pucker conformation (C19–O19–C49–S39
torsional angle of 8.5(2)u) and the 59-hydroxyl group is bonded to
Fig. 1 Calculated (vertical bars) and room-temperature (298 K) experi-
mental X-ray powder diffractograms (continuous line with dots) of (a)
lamivudine hydrogen phthalate and (b) lamivudine salicylate monohy-
drate. The calculated diffractograms were simulated from the correspond-
ing crystal structures, determined at either 298 K (lamivudine hydrogen
phthalate) or 107.4 K (lamivudine salicylate monohydrate).
Fig. 2 Asymmetric units of (a) lamivudine hydrogen phthalate (298 K
structure) and (b) lamivudine salicylate monohydrate (107.4 K structure).
Hydrogens are drawn as arbitrary radius spheres and the ellipsoids of the
non-hydrogen atoms are at a 50% probability level.
Fig. 3 Superposition of the lamivudine conformer present in the
structure of the salt with maleic acid8 (blue sticks) with those in the salts
with (a) phthalic (green sticks) and (b) salicylic (red sticks) acids. The
hydrogen atoms have been hidden for clarity.
This journal is  The Royal Society of Chemistry 2012 CrystEngComm, 2012, 14, 4562–4566 | 4563
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the methylene sp3-hybridized carbon in the equatorial position on
the same side of the sulfur atom (O19–C49–C59–O59 and S39–C49–
C59–O59 dihedral angles measure 2176.4(2)u and 62.5(2)u). In
contrast, the cytosine and oxathiolane rings assume anti and C39-
endo pucker conformations in the lamivudine hydrogen maleate
and lamivudine saccharinate salts and the 59-hydroxyl oxygen is in
the axial position on the same side of the cytosine molecule in these
two salts.
Concerning the crystal packing of lamivudine hydrogen
phthalate, the 59-OH group of lamivudine is a hydrogen bond
donor to (phthalic acid)2 with the carbonyl oxygen of the carboxyl
group as an acceptor. This interaction assembles (lamivudi-
ne)+(phthalic acid)2 ion pairs along the (010) direction by
alternating the cations and anions into a one-dimensional (1D)
ribbon wherein each species is related to one another by
translation. This same 59-O–H…OLC hydrogen bond between
lamivudine and the counterion also occurs in the hydrogen maleate
and saccharinate salts of the drug, but molecules of (lamivudine)+
and (maleic acid)2 (or saccharinate) are related by a 21-screw axis
symmetry and alternate along the (001) direction to form a zigzag
1D ribbon instead (Fig. 4). In these two isostructural salts, there is
an N–H…OLC hydrogen bond between the cytosine rings of the
neighbouring lamivudine molecules, related by a 21-screw axis
symmetry along the (010) direction, whereas the cytosine rings do
not interact through hydrogen bonds in the lamivudine hydrogen
phthalate salt. In the former, the NH2 moiety of cytosine, through
its hydrogen atom which is not involved in the (lamivudi-
ne)+(phthalic acid)2 pairing, is a hydrogen bond donor to the
59-hydroxyl oxygen of the lamivudine unit, related by a 21-screw
axis symmetry parallel to the (010) direction. This interaction acts
as a cross-linker, keeping the linear ribbons running parallel to the
b axis in contact. To complete the crystal packing difference
between lamivudine hydrogen phthalate and the two antecedent
salts, the 59-hydroxyl oxygen of lamivudine is not a classical
hydrogen bond acceptor in the last two crystal phases.
The lamivudine salicylate structure also differs from those of the
hydrogen maleate and saccharinate salts. Indeed, lamivudine
salicylate crystallizes in the P21 monoclinic space group as a
monohydrate. One water molecule is present in the asymmetric
unit together with one (lamivudine)+(salicylic acid)2 ion pair,
assembled through two hydrogen bonds with cytosine as dual
donor to both oxygens of the carboxylate, such as in the pairing of
lamivudine with the phthalic acid counterion. To the best of our
knowledge, a solid state phase of lamivudine salicylate mono-
hydrate has been previously reported,14 although neither crystal
structure of this salt (including any possible solvate) has been
elucidated thus far. Likewise, a lamivudine salt with phthalic acid
has been reported in the literature,15 even though no information
on its structure has been available up to now. The lamivudine
conformation in our structure (Fig. 3) is related to those in
lamivudine maleate and lamivudine saccharinate. The cytosine and
oxathiolane rings adopt anti (the C2–N1–C19–O19 dihedral angle
measures 162.2(4)u) and C39-endo (the C29–C19–O19–C49 torsion
measures 211.8(5)u) conformations in the lamivudine salicylate
monohydrate, with its 59-hydroxyl oxygen in an axial position (the
O19–C49–C59–O59 and S39–C49–C59–O59 dihedral angles measure
70.6(5)u and 249.2(5)u), similar to both the hydrogen maleate and
saccharinate salts. Even the 59-hydroxyl hydrogen points in the
same direction in these salts. It is important to state that
comparisons between the 59-OH hydrogen atom positions in the
lamivudine salicylate monohydrate, lamivudine hydrogen maleate
and lamivudine saccharinate were possible due to the fact that
their coordinates have been accurately found from the refinement.
However, such a conformational similarity is not related to the
Fig. 4 One-dimensional ribbons of (a) lamivudine hydrogen phthalate, (b) lamivudine hydrogen maleate,8 and (c) lamivudine saccharinate7 are cross-
linked through N–H…O hydrogen bonds (arrows) in which the acceptor is either the 59-OH group [lamivudine hydrogen phthalate, panel (d)] or the
C2LO2 moiety (lamivudine hydrogen maleate and lamivudine saccharinate, panels (e) and (f)).
4564 | CrystEngComm, 2012, 14, 4562–4566 This journal is  The Royal Society of Chemistry 2012
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intermolecular interaction patterns. Lamivudine and water mole-
cules give rise to a helical chain along the (010) direction, in which
each 59-OH group functions as a hydrogen bond donor and
acceptor from water molecules that are related by a 21-screw axis
symmetry (Fig. 5). These chains are packed along the (100)
direction through two hydrogen bonds whose (salicylic acid)2
counterion has a dual role as a hydrogen bond acceptor. The same
carboxylate oxygen hydrogen-bonded to the NH2 hydrogen
involved in the ionic pairing is also a hydrogen bond acceptor to
the other amine hydrogen of a 21-screw axis symmetry related
lamivudine molecule (Fig. 6). Finally, the water molecule is also a
hydrogen bond donor to the anions by means of a non-classical
O–H…p interaction in which the p-system of the phenyl ring is an
acceptor moiety. The occurrence of this interaction is supported by
taking into account the relatively short separation between the
water H2w hydrogen and the centroid, calculated through the
phenyl carbons (CgB). The H2w…CgB distance is 2.98(6) A˚.
In conclusion, lamivudine hydrogen phthalate and lamivudine
salicylate monohydrate were prepared and their structures were
elucidated and interpreted based on the crystal assembly and
conformational analyses. Both salts differ from the hydrogen
maleate and saccharinate versions of the drug, even though the
lamivudine conformation in the salicylate salt monohydrate
resembles those of the two antecedent phases. Such structural
knowledge reported in this study may help to understand the solid
state properties, such as the solubility and dissolution kinetics,
related to the pharmaceutical performance, resulting in the
progression of the solid state chemistry of the drug.
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{ Preparation. For the crystallization batches of each salt, an amount of
lamivudine form II (10 mg, 0.04 mmol), whose authenticity and purity were
previously checked by single-crystal and powder X-ray diffraction
techniques, was dissolved in isopropyl alcohol (5 mL) with stirring for
5 min in a water bath (308 K). This solution was then allowed to cool
slowly to room temperature (298 K). Next, an equimolar quantity of the
counterion (7 mg of either phthalic acid or salicylic acid) was then added to
the newly cooled solution. The resulting mixture was shaken at room
temperature until the salt was completely dissolved. This solution was
allowed to evaporate slowly upon standing for 5 days at 298 K. Crystals as
prisms (lamivudine hydrogen phthalate) or extremely thin needles
(lamivudine salicylate monohydrate) were formed on the bottom of the
corresponding glass crystallizers.
§ Structure determination. Well-grown single crystals of the salts measuring
0.251 6 0.130 6 0.078 mm3 (lamivudine hydrogen phthalate) or 0.293 6
0.076 6 0.052 mm3 (lamivudine salicylate monohydrate) were selected for
X-ray diffraction data collection at room (298(2) K, lamivudine hydrogen
phthalate) or low (107.4(2) K, lamivudine salicylate monohydrate)
temperature. The X-ray diffraction data from lamivudine salicylate
Fig. 6 The dual role of the salicylic acid counterions as cross-linkers
between neighbouring helical chains in the lamivudine salicylate mono-
hydrate. The two N–H…O and O–H…p hydrogen bonds involving each
counterion as a cross-linker between the chains are shown on the bottom
of the depiction. Symmetry codes: (i) = x + 1, y 2 1, z, (ii) = 2 x + 2,
y 2 0.5, 2 z.
Fig. 5 (a) Lamivudine salicylate monohydrate is assembled as helical
chains made up of O–H…O hydrogen bonds between the 59-OH group
and water. (b) Top view of the helical chain projected onto the (010) plane.
This journal is  The Royal Society of Chemistry 2012 CrystEngComm, 2012, 14, 4562–4566 | 4565
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
D
A
D
 S
A
O
 P
A
U
LO
 o
n 
11
/0
4/
20
13
 1
3:
13
:0
7.
 
Pu
bl
ish
ed
 o
n 
25
 A
pr
il 
20
12
 o
n 
ht
tp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
2C
E2
538
6K
View Article Online
monohydrate had a low intensity even at medium resolution due to the
small dimensions of the crystal. For that reason, the X-ray diffraction
experiment for this salt was carried out at a low temperature. For
lamivudine hydrogen phthalate, a graphite-monochromated X-ray beam
(Mo–Ka radiation, l = 0.71073 A˚) was employed using a Kappa-CCD
diffractometer with a FR590 generator. In the case of lamivudine salicylate
monohydrate, X-ray diffraction data was measured on a Gemini A-Ultra
diffractometer equipped with an Atlas CCD detector. Graphite-mono-
chromated Cu–Ka radiation (l = 1.54184 A˚) was used in this case and a
multi-scan absorption correction was applied to the raw data set (Tmin =
0.66774, Tmax = 1.00000). The X-ray diffraction data was treated as
follows: cell refinement and data reduction were treated with HKL Denzo-
Scalepack16 and CrysAlis PRO17 software (there was no absorption
correction for lamivudine hydrogen phthalate due to small absorption
effects when using a Mo–Ka beam), solving by direct methods of phase
retrieval with SHELXS-97,18 refinement by full-matrix least squares on F2
using SHELXL-97,18 constrained positions and fixed isotropic thermal
parameters [Uiso(H) = 1.2Ueq(C)] for C–H hydrogen atoms following the
riding model, localization of N–H, N+–H and O–H hydrogen atoms from
the difference Fourier map and free refinement of their positions with fixed
isotropic thermal parameters [Uiso(H) = 1.2Ueq(N) or 1.5Ueq(O)], structure
analysis and preparation of the artwork using MERCURY19 and ORTEP-
3. 2 0 Crysta l data for lamivudine hydrogen phthalate .
(C8H12N3O3S)(C8H5O4), MW = 395.39, orthorhombic, a = 5.3990(1) A˚,
b = 15.7550(4) A˚, c = 20.6980(5) A˚, V = 1760.60(7) A˚3, T = 298(2) K, space
group P212121, Z = 4, Dc = 1.492 g cm
23, m(Mo–Ka) = 0.23 mm21, h-
range for data collection = 3.22–26.36, 26¡ h¡ 6, 219¡ k¡ 19, 225
¡ l ¡ 25, 7211 reflections collected, 3530 unique (Rint = 0.0360),
completeness to h = 26.36 of 98.4%, F000 = 824, 259 parameters refined, S =
1.022, R1(I > 2s(I)) = 0.0387, wR2(I > 2s(I)) = 0.0958, R1 (all data) =
0.0566, wR2 (all data) = 0.1042, largest diff. peak/hole = 0.135/20.187 e
A˚23, Flack parameter = 0.03(8) (1458 Friedel pairs). CCDC 871607.
C r y s t a l d a t a f o r l a m i v u d i n e s a l i c y l a t e m o n o h yd r a t e .
(C8H12N3O3S)(C7H5O3)(H2O), MW = 385.40, monoclinic, a =
12.7246(12) A˚, b = 5.2978(3) A˚, c = 13.1688(9) A˚, b = 106.129(8)u, V =
852.80(11) A˚3, T = 107.4(2) K, space group P21, Z = 2, Dc = 1.501 g cm
23,
m(Cu–Ka) = 2.106 mm21, h-range for data collection = 3.49–66.01, 215¡
h ¡ 14, 22 ¡ k ¡ 6, 215 ¡ l ¡ 15 5257 reflections collected, 2024
unique (Rint = 0.0651), completeness to h = 66.01 of 98.4%, F000 = 404, 256
parameters refined, S = 1.064, R1(I > 2s(I)) = 0.0429, wR2(I > 2s(I)) =
0.0933, R1 (all data) = 0.0598, wR2 (all data) = 0.1063, largest diff. peak/
hole = 0.279/20.370 e A˚23, Flack parameter =20.01(3) (375 Friedel pairs).
CCDC 871608
" For X-ray powder diffraction analysis, crystalline materials obtained
from crystallization procedures were powdered and mounted onto a sample
holder. Room temperature (298 K) X-ray powder diffractograms were
acquired using an X-ray beam (Cu–Ka radiation, l = 1.5418 A˚) generated
at 40 kV and 30 mA on a Shimadzu XRD-6000 diffractometer. The
diffractograms were acquired at room temperature under a continuous
scan mode (scan axis h–2h) with a scan speed of 1.000u min˜1. Intensity data
was measured at each 0.020u in a 2h range between 5u and 40u.
Crystallographic information files of the structures for lamivudine
hydrogen phthalate and lamivudine salicylate monohydrate were used to
simulate the X-ray diffractograms with PowderCell software21 in order to
compare them to the experimental set. It is important to emphasize that
single crystal X-ray data of lamivudine salicylate monohydrate was
measured at low temperature (107.4 K), while the experimental X-ray
powder diffractogram of this salt was acquired at room temperature.
Moreover, the comparison between the experimental and theoretical
diffractograms from the single crystal structure has allowed us to assign the
lamivudine salicylate monohydrate phase to the sample because corre-
sponding simulated and observed Bragg peaks were in agreeing 2h-
positions, even with the temperature difference.
I Orthorhombic cell parameters of lamivudine hydrogen maleate: a =
5.4130(1) A˚, b = 12.7870(4) A˚, c = 21.6501(7) A˚;8 and of lamivudine
saccharinate: a = 5.3464(6) A˚, b = 13.7459(14) A˚, c = 22.738(2) A˚.7 Both
structures were determined at a temperature of 100(2) K, while the X-ray
data of lamivudine hydrogen phthalate was measured at room temperature
(see crystal data for cell dimension comparisons).
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